Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023

SELL
$0.57 - $1.08 $18,302 - $34,678
-32,110 Reduced 11.18%
255,159 $153,000
Q1 2023

May 15, 2023

BUY
$0.66 - $1.29 $145,619 - $284,620
220,636 Added 331.12%
287,269 $215,000
Q4 2022

Feb 14, 2023

BUY
$1.1 - $2.45 $73,296 - $163,250
66,633 New
66,633 $82,000
Q4 2021

Feb 14, 2022

SELL
$5.37 - $7.07 $323,274 - $425,614
-60,200 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$5.54 - $7.51 $30,763 - $41,703
5,553 Added 10.16%
60,200 $372,000
Q2 2021

Aug 16, 2021

SELL
$7.78 - $11.4 $4.66 Million - $6.83 Million
-599,267 Reduced 91.64%
54,647 $464,000
Q1 2021

May 17, 2021

BUY
$5.12 - $8.48 $941,885 - $1.56 Million
183,962 Added 39.14%
653,914 $5.17 Million
Q4 2020

Feb 16, 2021

BUY
$3.16 - $7.03 $363,965 - $809,708
115,179 Added 32.47%
469,952 $2.74 Million
Q3 2020

Nov 16, 2020

BUY
$3.26 - $4.73 $141,043 - $204,643
43,265 Added 13.89%
354,773 $1.2 Million
Q2 2020

Aug 14, 2020

BUY
$1.58 - $4.63 $282,284 - $827,200
178,661 Added 134.49%
311,508 $1.44 Million
Q1 2020

May 15, 2020

SELL
$1.44 - $3.02 $14,623 - $30,668
-10,155 Reduced 7.1%
132,847 $210,000
Q4 2019

Feb 14, 2020

BUY
$2.25 - $3.07 $17,826 - $24,323
7,923 Added 5.87%
143,002 $392,000
Q3 2019

Nov 14, 2019

BUY
$2.67 - $3.65 $261,043 - $356,856
97,769 Added 262.05%
135,079 $397,000
Q2 2019

Aug 14, 2019

BUY
$2.6 - $4.21 $63,858 - $103,401
24,561 Added 192.65%
37,310 $107,000
Q1 2019

May 15, 2019

BUY
$3.05 - $4.34 $3,226 - $4,591
1,058 Added 9.05%
12,749 $54,000
Q4 2018

Feb 14, 2019

BUY
$2.82 - $4.67 $32,968 - $54,596
11,691 New
11,691 $36,000

Others Institutions Holding AFMD

About Affimed N.V.


  • Ticker AFMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,339,008
  • Market Cap $520M
  • Description
  • Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...
More about AFMD
Track This Portfolio

Track D. E. Shaw & Co., Inc. Portfolio

Follow D. E. Shaw & Co., Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.